ALKS 8700

Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Thu, 05/30/19 - 09:42 am
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership
Marketwatch
Mon, 11/27/17 - 09:10 am
Alkermes
Biogen
MS
multiple sclerosis
ALKS 8700
Alkermes says its more tolerable Tecfidera rival is ready for pivotal challenge
Fierce Biotech
Mon, 02/9/15 - 05:59 pm
Alkermes
ALKS 8700
MS
multiple sclerosis
Biogen Idec
Tecfidera